On Tuesday, Taysha Gene Therapies Inc (NASDAQ: TSHA) opened higher 22.76% from the last session, before settling in for the closing price of $1.45. Price fluctuations for TSHA have ranged from $1.05 to $4.32 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
During the last 5-year period, the sales growth of Healthcare Sector giant was 94.30%. Company’s average yearly earnings per share was noted -0.23% at the time writing. With a float of $165.06 million, this company’s outstanding shares have now reached $204.94 million.
Let’s determine the extent of company efficiency that accounts for 73 employees. In terms of profitability, gross margin is 100.0%, operating margin of -1097.55%, and the pretax margin is -1071.62%.
Taysha Gene Therapies Inc (TSHA) Breakdown of a Key Holders of the stock
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Taysha Gene Therapies Inc is 19.51%, while institutional ownership is 77.23%. The most recent insider transaction that took place on Jun 27 ’24, was worth 2,999,999. In this transaction 10% Owner of this company bought 1,333,333 shares at a rate of $2.25, taking the stock ownership to the 1,333,333 shares.
Taysha Gene Therapies Inc (TSHA) Recent Fiscal highlights
According to the Wall Street analysts, stocks earnings will be around -0.23% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 7.82% during the next five years compared to -63.99% drop over the previous five years of trading.
Taysha Gene Therapies Inc (NASDAQ: TSHA) Trading Performance Indicators
Check out the current performance indicators for Taysha Gene Therapies Inc (TSHA). In the past quarter, the stock posted a quick ratio of 5.41. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 43.82.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.38, a number that is poised to hit -0.09 in the next quarter and is forecasted to reach -0.44 in one year’s time.
Technical Analysis of Taysha Gene Therapies Inc (TSHA)
Looking closely at Taysha Gene Therapies Inc (NASDAQ: TSHA), its last 5-days average volume was 2.5 million, which is a jump from its year-to-date volume of 2.15 million. As of the previous 9 days, the stock’s Stochastic %D was 83.40%. Additionally, its Average True Range was 0.17.
During the past 100 days, Taysha Gene Therapies Inc’s (TSHA) raw stochastic average was set at 32.30%, which indicates a significant decrease from 94.81% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 125.55% in the past 14 days, which was higher than the 101.87% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $1.5674, while its 200-day Moving Average is $1.9311. However, in the short run, Taysha Gene Therapies Inc’s stock first resistance to watch stands at $1.9133. Second resistance stands at $2.0467. The third major resistance level sits at $2.2733. If the price goes on to break the first support level at $1.5533, it is likely to go to the next support level at $1.3267. Now, if the price goes above the second support level, the third support stands at $1.1933.
Taysha Gene Therapies Inc (NASDAQ: TSHA) Key Stats
There are currently 205,055K shares outstanding in the company with a market cap of 365.00 million. Presently, the company’s annual sales total 8,330 K according to its annual income of -89,300 K. Last quarter, the company’s sales amounted to 2,020 K and its income totaled -18,780 K.
